Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Jaeseung Lim Clear advanced filters

  • Tuberculosis kills more than a million people annually, and new treatments are necessary to counter the spread of drug-resistant forms of Mycobacterium tuberculosis. In this issue, Kevin Pethe and his colleagues report their identification of a new antibercular drug, called Q203, that targets the mycobacterial cytochrome bc1 complex and that showed efficacy in vitro and in vivo.

    • Kevin Pethe
    • Pablo Bifani
    • Jaeseung Kim
    Research
    Nature Medicine
    Volume: 19, P: 1157-1160

  • Organoid research can be limited by the lack of methods for producing uniformly mature organoids. Here, the authors present UniMat, an organoid culture platform featuring a 3D geometrically-engineered permeable membrane, which produces uniform and mature organoids by providing both geometrical constraints and unrestricted supply of factors.

    • Dohui Kim
    • Hyeonji Lim
    • Dong Sung Kim
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-18

  • Laser lift-off (LLO) is a widely utilized process in the manufacturing of flexible electronics, but its application to ultrathin polymeric films can be challenging. Here, the authors report a graphene-enabled LLO method to improve the processability of few-micron-thick polyimide films and organic light-emitting diodes without compromising their quality.

    • Sumin Kang
    • Jaehyeock Chang
    • Seungman Kim
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-10

  • Biotech company Cellatoz Therapeutics is developing innovative cell therapies by applying its proprietary cells, known as A-to-Z cells to multiple therapeutic areas. The company is now looking for partners to develop the therapies further.

    • Cellatoz Therapeutics, Inc.
    Advertorial
    Biopharma Dealmakers